Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 2, 2003, Pages 161-166

  Tsang, W P ^a   Chau, S P Y ^a   Fung, K P ^a   Kong, S K ^a   Kwok, T T ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Doxorubicin; Drug resistance; MRP1; p53 mutation

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; OLIGONUCLEOTIDE; PROTEIN P53;

ARTICLE; CELL LINE; CODON; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NULL CELL; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0037325522     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0551-2     Document Type: Article

References (29)

1. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG (1992) Overexpression of a transporter gene in multidrug resistant human lung cancer cell line. Science 258:1650-1654
2. Labroille G, Belloc F, Bilhou-Nabera C, Bonnefille S, Bascans E, Boisseau MR, Bernard P, Lacombe F (1998) Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry 32:86-94
3. Zhu Q, Center MS (1996) Evidence that SP1 modulates transcriptional activity of the multidrug resistance-associated protein gene. DNA Cell Biol 15:105-111
4. Borst R, Kool M, Evers R (1997) Do cMOAT (MRP2), other MRP homologues and LRP play a role in MDR? Semin Cancer Biol 8:205-213
5. Deeley R, Cole SPC (1997) Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8:193-204
6. Volm M, Mattern J (1996) Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncog 7:227-244
7. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 4:357-361
8. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113
9. Loe DW, Deeley RG, Cole SPC (1996) Biology of the multidrug or resistance-associated protein in MRP. Eur J Cancer 32A:945-957
10. Cole SP, Deeley RG (1998) Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20:931-940
11. Lee G, Piquette-Miller M (2001) Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 79:876-884
12. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstmann B, Kauffmann HM (2001) Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett 120:51-57
13. Yamane Y, Furuichi M, Song R, Van NT, Mulcahy RT, Ishikawa T, Kuo MT (1998) Expression of multidrug resistance protein/GS-X pump and γ-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem 273:31075-31085
14. Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM, Cotter FE (2002) In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy. Int J Cancer 98:128-133
15. Wang Q, Beck WT (1998) Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58:14517-14522
16. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN (2000) Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105:1261-1267
17. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific p53 mutations are associated with denovo resistance to doxorubicin in breast cancer patients. Nat Med 2:804-810
18. Chang FL, Lai MD (2001) Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J Urol 166:304-310
19. Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898
20. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP (2001) Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61:6185-6193
21. Levine AJ, Perry ME, Chang A (1994) The 1993 Walter Hubert Lecture - the role of p53 tumor suppressor gene in tumorigenesis. Br J Cancer 69:409-416
22. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79
23. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) Gain of function mutations in p53. Nat Genet 4:42-46
24. Esser J, Esser P, Mietz H, Hueber A, Kociok N, Schraermeyer U, Krieglstein GK (2000) Multidrug resistance-associated proteins in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol 238:727-732
25. Stewart AJ, Canitrot Y, Baracchini E, Dean NM, Deeley RG, Cole SPC (1996) Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 51:461-469
26. Deb S, Jackson CT, Subler MA, Martin DW (1992) Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66:6164-6170
27. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S (1996) Transcriptional activation of the human epidermal growth factor receptor promotor by human p53. Mol Cell Biol 16:6009-6019
28. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V (1993) The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8:1529-1535
29. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Kuo MT (2001) Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol 61:555-563